CymaBay Therapeutics Inc (NASDAQ:CBAY) shares saw unusually-strong trading volume on Wednesday . Approximately 2,620,100 shares traded hands during mid-day trading, an increase of 167% from the previous session’s volume of 981,873 shares.The stock last traded at $13.50 and had previously closed at $13.50.
A number of equities analysts have commented on CBAY shares. Piper Jaffray Companies restated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research report on Friday, October 27th. Oppenheimer set a $15.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 10th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Zacks Investment Research lowered shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. CymaBay Therapeutics has an average rating of “Buy” and an average target price of $16.56.
The company has a market capitalization of $592.17, a PE ratio of -13.77 and a beta of 2.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.39 and a quick ratio of 7.39.
Several institutional investors and hedge funds have recently bought and sold shares of CBAY. Perceptive Advisors LLC bought a new stake in shares of CymaBay Therapeutics during the third quarter worth approximately $18,948,000. Farallon Capital Management LLC bought a new stake in CymaBay Therapeutics in the fourth quarter valued at approximately $10,120,000. Citadel Advisors LLC bought a new stake in CymaBay Therapeutics in the third quarter valued at approximately $5,159,000. EAM Investors LLC bought a new stake in CymaBay Therapeutics in the third quarter valued at approximately $4,788,000. Finally, UBS Asset Management Americas Inc. bought a new stake in CymaBay Therapeutics in the fourth quarter valued at approximately $5,423,000. 54.80% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://sportsperspectives.com/2018/02/14/cymabay-therapeutics-cbay-sees-large-volume-increase.html.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.